Pattern of MAP kinase phosphatase, DUSP1, in human obesity, diabetes and cardiovascular diseases
Ali Tiss, PhD., Msc., Eng.
Senior Scientist / Head of Functional Proteomics and Metabolomics Unit, Dasman Diabetes Institute. Kuwait.
Dr. Tiss obtained his PhD in 2001 at the laboratory of Lipolytic Enzymes (CNRS, Marseille, France) where he carried out studies on Orlistat, an anti-obesity drug. In 2002, he joined the Laboratory of Mass Spectrometry (CEA, Grenoble, France) as a Post-doc and he worked on Protein-Protein and Protein-DNA interactions. In 2005, he joined the BioCentre (University of Reading, UK) and carried out researches on two collaborative projects in the field of proteomics; “UK collaborative trial for ovarian cancer screening (UKCTOCS)” and “System-wide analysis and modelling of type-2 diabetes mellitus”. In 2009, Dr. Tiss joined the Dasman Diabetes Institute newly founded in Kuwait where he set-up a state-of-the art proteomics platform and actually leading the Functional Proteomics and Metabolomics Research Unit. The main focus of his team is the early detection and prevention of diabetes and its complications using “omics” and clinical integrative approaches.
Ali Tiss et al.
Functional Proteomics and Metabolomics Unit, Dasman Diabetes Institute, Kuwait
Dual-specificity protein phosphatase 1 (DUSP1) is regulating the activity of MAP Kinases and is implicated in energy expenditure. We investigated the expression pattern of DUSP1 in normal-weight, non-diabetic and diabetic obese human subjects using subcutaneous adipose tissue and blood. A strong correlation of DUPS1 levels was observed with obesity indicators, inflammatory and metabolic markers which were then modulated by a 3-months moderate physical exercise intervention. We further investigated DUSP1 circulating levels in selected phenotypes of human cardiovascular disease (CVD) patients in a separate human cohort. CVD patients displayed higher levels of DUSP1 whereas no difference was seen in hsCRP levels when compared to their matched controls. Our results suggested that CVD patients are experiencing ongoing inflammation and that circulating DUSP1 might be considered as potential marker for residual risk and future CVD events